TVR5 retweeted
Delighted to bring a fresh look at #AVCT ESMO presentations from our TMED team. Our pre|CISION platform data inform HOW the durable release occurs. This is a masterclass in the feedback loop of information in biotech. An observation in Ph 1 explained in preclinical models.
In this Episode of the R&D Spotlight Series, the team discuss the key findings from our ESMO data. One important finding is that tumors recruit fibroblasts during treatment, leading to an increased ability to release the payload.
avacta.wistia.com/s/59m12mns… #AVCT
#AVCT will reveal its Gen3 drug AVA6207 next week.
AVA6207 is, at its core, AVA6103 plus an additional docking site.
A working AVA6103 greatly increases the value of AVA6207.
The owner of the ATRi warhead has a direct interest in the AVA6103 biopsies which are now rolling in.
In this Episode of the R&D Spotlight Series, the team discuss the key findings from our ESMO data. One important finding is that tumors recruit fibroblasts during treatment, leading to an increased ability to release the payload.
avacta.wistia.com/s/59m12mns… #AVCT
#AVCT releases the warheads which will make up AVA6207 next week.
The foundation of AVA6207 is AVA6103. Now proven in human.
Ownership of the ATR inhibitor, which will sit alongside Exatecan in AVA6207, will be highly informative.
Who owns the green payload AVCT seeks to use?
“Always important to have the ‘safe bets’ as well as the moonshots that exist under the surface.”
AVA6103 7+ months into clinic at this point; through 5 cohorts; across 6 indications; and backfilling with mandatory biopsies.
October was always a very important month for #AVCT.
Great discussion today at the @LongwoodLeaders forum in Boston on prioritizing the pipeline. Delighted to discuss the #AVCT pipeline & how we make hard decisions: sure bets v. Moonshots and those between. Big pharma and biotech have similar priority: patient impact
#LetsDoThis
Our CEO Christina Coughlin participating in the Prioritizing the Pipeline panel with @LongwoodLeaders in Boston today, discussing how we assess our platform opportunities to deliver high patient impact. #AVCT lnkd.in/p/ePwyn4yx
CEO Christina Coughlin and CFO Brian Hahn will be at @Jefferies Healthcare Conference, Nov 16-19 in London. Curious how pre|CISION® keeps potent payloads silent in the bloodstream and active in the tumor? Book a 1:1 via the partnering system. avacta.com/avacta-participat… #AVCT
Great insight into what went into getting #AVCT’s AVA6103 into the clinic in 14 months:
200+ PDCs synthesised
400+ compounds screened
40+ warheads evaluated
Also interesting the patent included x3 Sygnature Discovery inventors.
AVA6103 featured in a new case study this morning by #AVCT partner CRO Sygnature Discovery
sygnaturediscovery.com/case-…
#AVCT’s AVA6103 works.
“Mechanistically, the sustained release mechanism is playing out as we expect.”
“Findings increase confidence that the nonclinical-to-clinical translation is performing as intended - exactly as we anticipated.”
Watch episode 16 of our R&D Spotlight series, where Avacta Chief Executive Officer @coughlin582 takes a deep dive into the AVA6103 data presented at ESMO 2026. avacta.wistia.com/s/xs4ra3k8… #AVCT
















